Press Releases » Business Wire IndiaPosted at: Jun 4 2026 4:05PM


First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment

Mumbai, Maharashtra, India

Approval introduces Pulsed Field Ablation technology to India. The VARIPULSE™ Platform is the first Pulsed Field Ablation system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and procedural accuracy.1, i, ii, iii, iv, v, vi, vii, viii, ix

 

Johnson & Johnson* today announced the approval of the VARIPULSE™ Platform, India’s first Pulsed Field Ablation (PFA) technology that has been used to perform catheter ablation procedures for atrial fibrillation (AFib) in more than 80,000 procedures globally.2 AFib is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria and is associated with structural changes in the heart due to underlying conditions and lifestyle factors.x, xi It significantly increases the risk of stroke, heart failure, and mortality.

 

Atrial Fibrillation affects 50 million people worldwide,xii representing a burden comparable to heart failure, which impacts over 64 million people globally.xiii In India, AFib prevalence is estimated at 0.1% to 1.6% of the population, with approximately 5 million people currently living with the condition.xiv, xv, xvi Indian patients develop AFib nearly a decade earlier than those in Western populations, at an average age of around 55 years, extending the long-term disease burden.xvii, xviii Underlying AFib in India is detected at the time of stroke in 20–45% of cases.xix As a progressive condition, early intervention in AFib is critical to reducing stroke risk, particularly given that India accounted for 773,000 stroke deaths in 2021, or 10% of global stroke deaths.xx

Catheter ablation is a minimally invasive procedure used to restore normal heart rhythm by treating areas responsible for abnormal electrical signals. PFA is a catheter ablation technique that uses short, high-voltage electrical pulses to target cardiac cells by creating pores in cell membranes, leading to cell death. It has the potential to offer safe, consistent, and efficient therapy for AFib treatment.xxi

 

The VARIPULSE™ Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO™ 3 System. This 3D electroanatomical cardiac mapping technology enables real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy for physicians treating patients with atrial fibrillation (AFib).xxii It enables safe and efficient i,ii, iii, iv,v, vi,vii patient-centric therapy with minimal to no fluoroscopy exposure xxiii,xxiv, xxv and is compatible with deep and/or conscious sedation.3, xxvi, xxvii

 

“The approval of the VARIPULSE™ Platform in India marks an important milestone in advancing AFib treatment,” said Randeep Sharma, General Manager, India, Electrophysiology, MedTech, Johnson & Johnson. “Pulsed field ablation is gaining momentum globally, and bringing an integrated platform like VARIPULSE™ to India will enable physicians to deliver more precise and efficient care for AFib patients.”

 

The innovation is backed by compelling clinical evidence with the most recent real-world evidence demonstrating strong safety and effectiveness of the VARIPULSE™ Platform:

 

  • VARIPURE– the largest prospective real-world dataset for the VARIPULSE™ Platform in Europe–reported a favorable 12-month interim effectiveness, including:

    • 84.2% freedom from documented atrial arrhythmia recurrence at 12 months,4 based on Kaplan–Meier estimates.xxviii

    • A strong safety profile with 0.8% primary adverse event (PAE) rate and zero reported strokes, coronary spasm or other PFA-related complications. xxviii,5

  • Real AF– an observational, prospective, multicenter registry in US and Canada designed to obtain real-world clinical experience using the VARIPULSE Platform–reported: xxix

    • A strong safety profile with a 0.6% primary adverse event rate and zero reported strokes, coronary spasm, or other PFA-related complications.6

    • 86.5% same day discharge.

 

“In India, where the disease burden is significant, access to care is complex, continued innovation in treatment approaches is especially relevant.” said Dr. Dhanunjaya Lakkireddy, Executive Medical Director and Professor of medicine at the Kansas City Heart Rhythm Institute, 7 “Pulsed Field Ablation is a rapidly emerging technology, that can revolutionize arrhythmia care in India as it did with the rest of the world. Its adoption in India will require continued clinical evaluation and appropriate training to ensure safe and effective use. Integration of PFA technology with 3D mapping empowers heart rhythm specialists with superior therapeutic tools that can significantly improve quality of healthcare for patients.”

 

Note: ’First in India’ claim is based solely on the chronology of regulatory approval/registration granted by the applicable Indian regulatory authority.

 

* The local legal entity in India is Johnson & Johnson Private Limited

 

1 When compared to procedures that did not use navigation systems.

2 As of May 2026

3 Based on a subset of 29 deep sedation patients from the inspIRE study and 60 patients in inpsIRE study. Procedures completed under sedation vs general anesthesia had comparable safety rates and procedure times, demonstrating safety and procedural efficiency.

4 Freedom from documented (symptomatic and asymptomatic) atrial arrythmia recurrence with episodes ≥30 seconds recorded by ECG after a 3-month blanking period

5 Patients without at least 90 days of follow-up are excluded from the safety evaluation unless they experienced a PAE

6 All safety events were assessed up to 90 days, as available

7 Dr. Lakkireddy serves as a consultant for Johnson & Johnson but was not compensated for this announcement

 

About the VARIPULSE™ Platform

The VARIPULSE™ Platform is Johnson & Johnson MedTech’s Pulsed Field ablation system. The fully integrated platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Software.

 

Cardiovascular Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.

 

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

 

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the VARIPULSETM Platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

General Disclaimer:

The VARIPULSE™ Platform is a medical device and should be used only by appropriately trained healthcare professionals in accordance with the approved indications, applicable labelling, and instructions for use in India. This press release is intended solely for informational purposes and should not be construed as medical advice, a solicitation to patients, or a substitute for the independent clinical judgment of a qualified healthcare professional. Individual patient outcomes may vary, and treatment decisions should be made by the treating physician based on the patient’s clinical condition and applicable medical guidance.

 

© Johnson & Johnson and its affiliates 2026. All rights reserved. [IN_ELP_THER_416974]

Johnson & Johnson Private Limited

Arena Space, Behind Majas Bus Depot, Off J.V. Link Road, Jogeshwari (East), Mumbai, Maharashtra, India, 400 060

 

[i] Duytschaever M, De Potter T, Grimaldi M, et al. Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE Study. Circ Arrhythm Electrophysiol. 2023;16(3):e011780. doi:10.1161/CIRCEP.122.011780 pg 4

[ii] Reddy VY, Calkins H, Mansour M, Wazni O, Di Biase L, Bahu M, Newton D, Liu CF, Sauer WH, Goyal S, Iyer V, Nair D, Athill C, Hussein A, Whalen P, Melby D, Natale A; AdmIRE Trial Investigators. Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial. Circulation. 2024 Oct 8 pg 8

[iii] Anter, E., Mansour, M., Nair, D.G. et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med 30, 2303–2310 (2024). https://doi.org/10.1038/s41591-024-03022-6 pg 2

[iv] Reddy VY, Lehmann JW, Gerstenfeld EP, Mugglin AS, Schneider CW, Achyutha AB, Mansour M. A randomized controlled trial of pulsed field ablation versus standard-of-care ablation for paroxysmal atrial fibrillation: The ADVENT trial rationale and design. Heart Rhythm O2. 2023 Mar 8;4(5):317-328. doi: 10.1016/j.hroo.2023.03.001. PMID: 37323994; PMCID: PMC10264259. Pg 6

[v] VOLT CE Mark Study: Long-term safety and effectiveness of de novo PVI intreating AF. pg 3

[vi] Scherr D, Turagam MK, Maury P, Blaauw Y, van der Voort P, Neuzil P, et al. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. Europace. 2025;2025(1):euaf012. doi:10.1093/europace/euaf012. Pg 4 results section

[vii] Seemala SKR, Musikantow DR, Perdomo C, Malyshev Y, Ambesh P, Saleem M, et al. Pulsed field ablation (PFA) to treat atrial fibrillation and related arrhythmias: one-year outcomes of the VIRTUE trial. Poster PO-FP-006. Pg 1

[viii] Fink T, Sciacca V, Bannmann K, et al. First experience using a novel variable loop catheter for mapping and pulsed field ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2025 May;48(5):471-479. doi:10.1111/pace.15177. Epub 2025 Mar 28. PMID:40153431; PMCID:PMC12063197

[ix] Fink T, Sciacca V, Bannmann K, et al. First experience using a novel variable loop catheter for mapping and pulsed field ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2025 Mar 28. doi:10.1111/pace.15177. Epub ahead of print. PMID: 40153431.

[x] Laizzo PA. Handbook of Cardiac Anatomy, Physiology, and Devices. 2015. Springer Science+Business Media. LLC: Switzerland

[xi] Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017;120(9):1501-1517

[xii] Tan S, Zhou J, Veang T, Lin Q, Liu Q. Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046—a systematic analysis of the Global Burden of Disease Study 2021. EP Europace. 2025;27(2):euaf027. doi:10.1093/europace/euaf027

[xiii] Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJSC. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272‑3287. doi:10.1093/cvr/cvac013

[xiv] Soni A, Karna S, Fahey N, Sanghai S, Patel H, Raithatha S, Thanvi S, Nimbalkar S, Freedman B, Allison J, McManus DD. Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. Int J Cardiol. 2019 Apr 1;280:84-88. doi: 10.1016/j.ijcard.2018.12.016.

[xv] Saggu DK, Sundar G, Nair SG, Bhargava VC, Lalukota K, Chennapragada S, Narasimhan C, Chugh SS. Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study. Heart Asia. 2016 Apr 18;8(1):56-9. doi: 10.1136/heartasia-2015-010674

[xvi] Gupta R . Recent trends in coronary heart disease epidemiology in India. Indian Heart J 2008;60:B4–B18.

 [xvii] Vora, A, Kapoor A, Nair M, et al. Clinical presentation, management, and outcomes in the Indian heart rhythm society-atrial fibrillation (IHRS-AF) registry. Indian Heart J, 69 (1) (2017), pp. 43-47

 [xviii] Sharma YP, Batta A, Makkar K, et al.. Angiographic profile and outcomes in persistent non-valvular atrial fibrillation: a study from tertiary care center in North India. Indian Heart J, 74 (1) (2022), pp. 7-12

[xix] Dalal, J., Poncha, F., Bansal, S., Das, A., Gupta, P., Ghosh, D., … Mali, M. (2022). Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review. Curēus (Palo Alto, CA), 14(5), e25102–e25102. https://doi.org/10.7759/cureus.25102

[xx] Feigin V, Abate M, Abate Y et al.Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 The Lancet Neurology, 23, 973-1003 Ex

[xxi]Chun KRJ, Miklavčič D, Vlachos K, Bordignon S, Scherr D, Jaïs P, Schmidt B. State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective. EP Europace. 2024;26(6):euae134. doi:10.1093/europace/euae134.

[xxii] Di Biase L, Zou F, Lin AN, et al. Feasibility of Three-Dimensional Artificial Intelligence Algorithm Integration with Intracardiac Echocardiography for

Left Atrial Imaging During Atrial Fibrillation Catheter Ablation. Europace. 2023 Aug 2;25(9):euad211.

[xxiii] Debreceni D, Janosi K, Bocz B, et al. (2023). Zero fluoroscopy catheter ablation for atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med;10:1178783. doi: 10.3389/fcvm.2023.1178783

[xxiv] Rajendra A, Hunter TD, Morales GX, et al. (2023). Steerable sheath visualizable under 3D electroanatomical mapping facilitates paroxysmal atrial fibrillation ablation with minimal fluoroscopy. J Interv Card Electrophysiol;66(2):381-388. doi: 10.1007/s10840-022-01332-8.

[xxv] Tahin T, Riba A, Nemeth B, et al. (2021). Implementation of a zero fluoroscopic workflow using a simplified intracardiac echocardiography guided method for catheter ablation of atrial fibrillation, including repeat procedures. BMC Cardiovasc Disord;21(1):407. doi: 10.1186/s12872-021-02219-8.

[xxvi] Grimaldi M, Quadrini F, Caporusso N, et al. Deep sedation protocol during atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter. Europace. 2023;25(9):euad222. doi:10.1093/europace/euad222. PMID: 37470452; PMCID: PMC10434733.

[xxvii] De Potter T, Grimaldi M, Duytschaever M, Anic A, Vijgen J, Neuzil P, Van Herendael H, Verma A, Skanes A, Scherr D, Pürerfellner H, Rackauskas G, Jais P, Reddy VY, et al; inspIRE Trial Investigators. Predictors of success for pulmonary vein isolation with pulsed-field ablation using a variable-loop catheter with 3D mapping integration: complete 12-month outcomes from inspIRE. Circ Arrhythm Electrophysiol. 2024;17(5):e012667. doi:10.1161/CIRCEP.123.012667. Epub 2024 Apr 24. PMID: 38655693; PMCID: PMC11111320.

[xxviii] Scherr D, Bessière F, Kronborg MB, et al; VARIPURE Investigators. Effectiveness of AF pulsed field ablation with a variable loop circular catheter: 12-month VARIPURE results. Presented at: PFA Summit: European Heart Rhythm Association (EHRA) Congress; April 11, 2025; Paris, France.

[xxi] Porterfield C, Krishnan K, Khaykin Y, et al. Variable Loop Circular Catheter Pulsed Field Ablation in Real-World Practice: Complication Rates Across Patient and Procedural Characteristics. Presented at HRS; April 24, 2026; Chicago, IL